LONDON - Arrow Therapeutics Ltd. raised more than £21 million in the first close of its second-round funding, which should enable it to advance two antiviral products into clinical trials next year and complete preclinical development of antibacterial leads. (BioWorld International)
LONDON - BioVex Ltd. raised £17 million in third-round funding, giving it the means to start a U.S. Phase II trial of its lead cancer vaccine, OncoVEX, and move ImmunoVEX into Phase I work. (BioWorld Today)
LONDON - BioVex Ltd. raised £17 million in third-round funding, giving it the means to start a U.S. Phase II trial of its lead cancer vaccine, OncoVEX, and move ImmunoVEX into Phase I work. (BioWorld Today)
